These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Insulin detemir (levemir), a new long-acting insulin. Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022 [TBL] [Abstract][Full Text] [Related]
27. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus. Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465 [TBL] [Abstract][Full Text] [Related]
28. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections. Bode BW Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065 [TBL] [Abstract][Full Text] [Related]
29. Human insulin-induced lipoatrophy. Successful treatment using a jet-injection device. Logwin S; Conget I; Jansa M; Vidal M; Nicolau C; Gomis R Diabetes Care; 1996 Mar; 19(3):255-6. PubMed ID: 8742573 [TBL] [Abstract][Full Text] [Related]
30. Associations of insulin-induced lipodystrophy in children, adolescents, and young adults with type 1 diabetes mellitus using recombinant human insulin: a cross-sectional study. Singha A; Bhattacharjee R; Dalal BS; Biswas D; Choudhuri S; Chowdhury S J Pediatr Endocrinol Metab; 2021 Apr; 34(4):503-508. PubMed ID: 33662195 [TBL] [Abstract][Full Text] [Related]
31. Detemir plus aspart and glulisine induced lipoatrophy: 2015 literature review and report of a new case. Saberi S; Esfandiari NH; MacEachern MP; Tan MH Clin Diabetes Endocrinol; 2015; 1():10. PubMed ID: 28702229 [TBL] [Abstract][Full Text] [Related]
32. Continuous subcutaneous insulin infusion allows tolerance induction and diabetes treatment in a type 1 diabetic child with insulin allergy. Hasselmann C; Pecquet C; Bismuth E; Raverdy C; Sola-Gazagnes A; Lobut JB; Carel JC; Tubiana-Rufi N Diabetes Metab; 2013 Apr; 39(2):174-7. PubMed ID: 23206896 [TBL] [Abstract][Full Text] [Related]
33. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Richardson T; Kerr D Am J Clin Dermatol; 2003; 4(10):661-7. PubMed ID: 14507228 [TBL] [Abstract][Full Text] [Related]
34. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Monami M; Marchionni N; Mannucci E Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286 [TBL] [Abstract][Full Text] [Related]
35. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154 [TBL] [Abstract][Full Text] [Related]
36. Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus. Danne T Clin Ther; 2007; 29 Suppl D():S145-52. PubMed ID: 18191066 [TBL] [Abstract][Full Text] [Related]
37. Nausea and vomiting due to insulin glargine in patient with type 1 diabetes mellitus. Dixon AN; Bain SC BMJ; 2005 Feb; 330(7489):455. PubMed ID: 15731143 [No Abstract] [Full Text] [Related]
38. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Garg SK; Gottlieb PA; Hisatomi ME; D'Souza A; Walker AJ; Izuora KE; Chase HP Diabetes Res Clin Pract; 2004 Oct; 66(1):49-56. PubMed ID: 15364161 [TBL] [Abstract][Full Text] [Related]